Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03046355 · ClinicalTrials.gov registry record · NA
Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women
A NA study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03046355: Completed NA study, sponsored by The University of Texas Health Science Center, Houston.
NCT03046355 is a NA study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03046355, a NA study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The goal of the study is to determine whether labor induction at 37 weeks of pregnancy can improve the baby's health at birth when compared with delivery at a later point in the pregnancy.
Primary Outcome
NICHD is National Institute of Child Health and Human Development The NICHD nomogram will indicate their birth weight percentile based on their gestational age and ethnicity
Interventions
- PROCEDURE Labor induction at 37.0 to 37.6 weeks of gestation
- PROCEDURE Expectant monitoring until delivery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2019-03-18 |
| Phase | NA |
What the finished NCT03046355 record still lists
NCT03046355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Labor induction at 37.0 to 37.6 weeks of gestation is the first listed.
NCT03046355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03046355 about?
NCT03046355 is a clinical study titled "Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women". The goal of the study is to determine whether labor induction at 37 weeks of pregnancy can improve the baby's health at birth when compared with delivery at a later point in the pregnancy.
What is the current status of trial NCT03046355?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2017-03-13. Estimated completion is 2019-03-18.
What interventions are being tested in trial NCT03046355?
The interventions under investigation include: Labor induction at 37.0 to 37.6 weeks of gestation (PROCEDURE), Expectant monitoring until delivery (PROCEDURE).
Who is sponsoring clinical trial NCT03046355?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03046355's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI